Navigation Links
US Peripheral Vascular Device Market to Grow Strongly to $3.3 Billion by 2017

TORONTO, Jan. 23, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, increasing awareness and diagnosis of peripheral vascular disease (PVD) along with the introduction of improved next-generation devices will lead the United States peripheral vascular (PV) device market to grow strongly to reach $3.3 billion by 2017.

(Logo: )

Lower extremity treatment will grow substantially, as physicians and device manufacturers continue to focus on the prevention of limb amputation. A variety of recent and upcoming device launches, including drug eluting stents (DES) and drug-coated balloons (DCB), as well as improvements in lower-extremity stents will provide physicians with more options for treating lower extremity peripheral artery disease (PAD).

Growth in the femoral-popliteal (fem-pop) indication will be particularly strong. Historically, concerns about stent fractures have restrained their use, but next-generation devices offer improved flexibility and strength to address this issue. For example, Covidien recently released its Protege EverFlex and Flexible Stenting Solutions released its FlexStent, while IDEV Technologies is anticipated to receive FDA approval for use of the SUPERA VERITAS stent in the fem-pop arteries before 2015.

Furthermore, continued adoption of and physician familiarity with chronic total occlusion (CTO) devices will allow for endovascular treatment of increasingly challenging lesions in these indications, driving overall procedure volumes. In addition to the large players, including Boston Scientific, C. R. Bard, Cordis, Covidien, and Medtronic, this segment has attracted a number of niche competitors such as Avinger, Baylis Medical, and Spectranetics; these companies will be likely acquisition targets for larger competitors looking to expand their lower-extremity PV offerings.

"Aortic stent grafts will be the strongest growing peripheral vascular device segment, spurred by continual device improvement efforts by manufacturers," said MRG Analyst Louise Murphy . "A number of new manufacturers have begun to enter the US market, based on its favorable climate and the need for niche devices and innovations."

Smaller new competitors in the abdominal aortic stent graft segment include Endologix, Aptus Endosystems and TriVascular, with Lombard Medical and Bolton Medical expected to enter the market before 2017. Device innovations such as fenestrated grafts, low-profile devices and improved fixation mechanisms will help differentiate competitors and drive market growth.

Millennium Research Group's US Markets for Peripheral Vascular Devices report includes unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for peripheral vascular (PV) stents, percutaneous transluminal angioplasty (PTA) balloon catheters, chronic total occlusion (CTO) crossing devices, embolic protection devices (EPD), aortic stent grafts, synthetic surgical grafts, and PV accessory devices sold in the United States.

About Millennium Research Group
Millennium Research Group (, a Decision Resources Group company (, is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group

Alex Jablokow
Millennium Research Group

SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Peripheral Vascular Devices Market to 2018 - Increasing Demand for Minimally Invasive Endovascular Procedures Presents Growth Opportunities for Manufacturers
2. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
3. Anesthesia Equipment and Associated Peripherals: Advanced, Patient-Friendly Devices Will Sustain Market Growth in Europe, States Frost & Sullivan
4. Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
5. Global Peripheral Vascular Devices Market 2011-2015
6. Brazil Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others
7. North America Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology Prosthetic Heart Valves and Others
8. European Markets for Peripheral Vascular Devices 2012
9. European Market for Peripheral Vascular Devices
10. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
11. Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
Post Your Comments:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):